Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes

Carlos Gonzalez-Quesada, Nikolaos G. Frangogiannis

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalCurrent atherosclerosis reports
Volume11
Issue number2
DOIs
StatePublished - Mar 2 2009
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes'. Together they form a unique fingerprint.

  • Cite this